Diffuse Large B-cell Lymphoma (DLBCL) - Phase II
What is the Purpose of this Study?
If you choose to join this study, you will:
- Be given a lower dose of radiation over 10-13 radiation treatments
- Have information from tests, exams and procedures that are part of your medical care used for study purposes
-Be involved in the study for about 4-6 weeks
- Have your progress followed through your electronic medical records for up to 10 years after completion of study treatment.
- Be given a lower dose of radiation over 10-13 radiation treatments
- Have information from tests, exams and procedures that are part of your medical care used for study purposes
-Be involved in the study for about 4-6 weeks
- Have your progress followed through your electronic medical records for up to 10 years after completion of study treatment.
What is the Condition Being Studied?
Diffuse Large B-cell Lymphoma (DLBCL)
Who Can Participate in this Study?
Adults who:
- Have a diagnosis of stage I-IV DLBCL
- Have completed at least 3 treatments with chemo-immunotherapy
- Have no evidence of cancer in a PET-CT scan done after completion of chemotherapy
- Have a negative pregnancy test for women who can get pregnant
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to understand if lowering the radiation dose will work in maintaining high rates of disease control and lessen the short term and long term treatment side effects.
Study Details
Full Title
Phase II study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma
Principal Investigator
Contacts
Radiation Oncology DCI Clinical Research Team
Phone: +1 919-668-3726
Protocol Number
IRB:
PRO00100510
NCT:
NCT03681535
ClinicalTrials.gov
View on ClinicalTrials.gov